Pharma: Other News To Note
Friday, April 26, 2013
Actavis Inc., of Parsippany, N.J., reached a settlement agreement with Shire plc, of Dublin, Ireland, resolving patent litigation related to Actavis' generic version of INTUNIV (guanfacine hydrochloride) to treat attention deficit hyperactivity disorder. In October 2012, the FDA granted approval of Actavis' abbreviated new drug application.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.